Hims & Hers Soars 64% in Three Days as Novo Nordisk Deal Opens Door to GLP-1 Market
AI Podcast
Hims & Hers shares surged following a strategic collaboration with Novo Nordisk to sell GLP-1 medications like Ozempic and Wegovy. This partnership shifts Hims & Hers from generic to brand-name drug sales, enhancing user trust and platform stickiness. Citigroup views this as a pivotal moment, raising its price target based on the projected growth of the GLP-1 market. The collaboration also expands Novo Nordisk's digital reach. Additionally, Hims & Hers appointed a former Eli Lilly executive to bolster its communications strategy, signaling a move towards becoming a mainstream healthcare provider. This fundamental shift is expected to position Hims & Hers as a key beneficiary of the weight-loss drug trend.
TradingKey - Hims & Hers Health (HIMS.US) shares have surged nearly 64% over three trading days this week, rising more than 10% during intraday trading on Wednesday.
The company officially announced a strategic collaboration with global weight-loss drug giant Novo Nordisk (NVO.US) to sell brand-name medications on its platform, including Ozempic and Wegovy (including the highly anticipated oral tablets).
From 'Generic' to 'Brand-Name': A Strategic Qualitative Shift
This collaboration marks a definitive breakthrough for Hims & Hers, moving beyond its previous reliance on compounded and generic drugs to officially enter the core field of brand-name drug sales. Leveraging its established one-stop telehealth model of 'online consultation + prescription + delivery,' Hims & Hers will directly bring Novo Nordisk's flagship GLP-1 medications to millions of young, high-spending users.
Citigroup (C) defined this event as a 'pivotal moment' in Hims & Hers' history in its latest research report. Analysts noted that the introduction of brand-name drugs will significantly enhance user trust and retention on the platform, driving the company's transformation from a 'low-cost traffic model' to a 'high ticket size, high margin, and high stickiness' chronic disease management giant.
Citi maintained its Buy rating and significantly raised its price target, believing that the compound annual growth rate of over 30% in the GLP-1 market between 2026 and 2030 will provide Hims & Hers with massive incremental upside.
The partnership between Hims & Hers and Novo Nordisk also represents a key step forward for Novo Nordisk's distribution channels. Beyond traditional pharmacies and hospital systems, Novo Nordisk urgently needs digital channels to penetrate younger demographics who prioritize privacy and convenience—a gap that Hims & Hers happens to fill.
Former Eli Lilly Executive Joins to Strengthen Brand Moat
Simultaneous with the partnership news, Hims & Hers announced the appointment of Kathryn Beiser as Head of Communications. Beiser previously served at competitor Eli Lilly (LLY.US) for five years, where she spearheaded the global communication strategies for blockbuster GLP-1 drugs such as Mounjaro and Zepbound.
Market analysis suggests that Kathryn Beiser brings not only experience in branding high-end pharmaceuticals but also a 'firewall' for managing complex PR crises and establishing a professional, credible image.
This indicates that Hims & Hers is fully preparing for the leap from an 'internet-famous pharmacy' to a 'mainstream healthcare provider.'
Market analysts believe that Hims & Hers' surge this week is not mere emotional speculation, but a fundamental reconstruction of its underlying logic. Through its alliance with Novo Nordisk and the recruitment of top talent, the company is redefining the value proposition of telehealth in the GLP-1 era.
In the short term, the stock price may fluctuate due to profit-taking, but in the medium to long term, if the collaboration is successfully implemented, Hims & Hers is poised to become the biggest channel beneficiary of this wave of weight-loss drugs.
